DrugPatentWatch Database Preview

Deferiprone - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for deferiprone and what is the scope of patent protection?

Deferiprone is the generic ingredient in two branded drugs marketed by Chiesi, Hikma, and Taro Pharm Inds Ltd, and is included in five NDAs. There are five patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Deferiprone has fifty-four patent family members in twenty-seven countries.

There are four drug master file entries for deferiprone. Four suppliers are listed for this compound.

Summary for deferiprone

International Patents:	54
US Patents:	5
Tradenames:	2
Applicants:	3
NDAs:	5
Drug Master File Entries:	4
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	111
Clinical Trials:	58
Patent Applications:	1,450
Formulation / Manufacturing:	see details
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for deferiprone
What excipients (inactive ingredients) are in deferiprone?	deferiprone excipients list
DailyMed Link:	deferiprone at DailyMed

Recent Clinical Trials for deferiprone

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
First Affiliated Hospital of Fujian Medical University	Early Phase 1
David Hasan	Phase 2
Ministry of Health, France	Phase 2/Phase 3

See all deferiprone clinical trials

Pharmacology for deferiprone

Drug Class	Iron Chelator
Mechanism of Action	Iron Chelating Activity

Anatomical Therapeutic Chemical (ATC) Classes for deferiprone

V03AC	Iron chelating agents
V03A	ALL OTHER THERAPEUTIC PRODUCTS
V03	ALL OTHER THERAPEUTIC PRODUCTS
V	Various

Paragraph IV (Patent) Challenges for DEFERIPRONE

Tradename	Dosage	Ingredient	NDA	Submissiondate
FERRIPROX	TABLET;ORAL	deferiprone	021825	2016-01-29

US Patents and Regulatory Information for deferiprone

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chiesi	FERRIPROX	deferiprone	TABLET;ORAL	212269-001	May 19, 2020		RX	Yes	Yes
Hikma	DEFERIPRONE	deferiprone	TABLET;ORAL	213239-001	Mar 29, 2021	AB	RX	No	No
Chiesi	FERRIPROX	deferiprone	TABLET;ORAL	021825-002	Jul 25, 2019		RX	Yes	No
Chiesi	FERRIPROX	deferiprone	SOLUTION;ORAL	208030-002	Apr 20, 2018		RX	Yes	No			Y
Chiesi	FERRIPROX	deferiprone	TABLET;ORAL	021825-001	Oct 14, 2011	AB	RX	Yes	Yes
Chiesi	FERRIPROX	deferiprone	TABLET;ORAL	212269-001	May 19, 2020		RX	Yes	Yes			Y

Expired US Patents for deferiprone

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Chiesi	FERRIPROX	deferiprone	TABLET;ORAL	021825-001	Oct 14, 2011
Chiesi	FERRIPROX	deferiprone	SOLUTION;ORAL	208030-002	Apr 20, 2018
Chiesi	FERRIPROX	deferiprone	TABLET;ORAL	212269-001	May 19, 2020
Chiesi	FERRIPROX	deferiprone	TABLET;ORAL	021825-002	Jul 25, 2019
Chiesi	FERRIPROX	deferiprone	SOLUTION;ORAL	208030-001	Sep 9, 2015

International Patents for deferiprone

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2009129592
Eurasian Patent Organization	022751
Germany	60138189
Ukraine	102254
Cyprus	1116146
South Africa	200109322